Drug intelligence / Profile preview

GemAGY

Development stage: Preclinical
Lead developer: Florida Agricultural and Mechanical University
Modality: Small Molecules
Administration: Intravenous

Overview

GemAGY is a novel gemcitabine analog developed to overcome the rapid metabolic deamination of gemcitabine in the blood. It was synthesized by chemical modification of gemcitabine hydrochloride at the N4 position with hydroxylamine. In preclinical studies, GemAGY demonstrated significantly higher cytotoxic activity against pancreatic cancer cell lines (MiaPaCa-2, BxPC3, and PANC-1) compared to gemcitabine, with lower IC50 values. The modification aims to improve metabolic stability and limit resistance mechanisms common in pancreatic cancer treatment. GemAGY works by inducing apoptosis, inhibiting cell migration, and causing cell cycle arrest in the G0/G1 phase.

Other names: gemcitabine analog

Targets

RNR (Ribonucleotide reductase)DNA

Beyond the preview

Go deeper on GemAGY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GemAGY.

Explore the full profile